SCHEMBL1684913

SCHEMBL1684913

COc1ccc(Nc2nc(-c3c(C)nc4ncccn34)cs2)cc1Cl

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.72
▸ GAA P10253 8/20 0.72
▸ ALDH1A1 P00352 7/20 0.72
▸ KMT2A Q03164 4/20 0.72
▸ HTT P42858 4/20 0.72
▸ MEN1 O00255 3/20 0.72
▸ MAPK1 P28482 2/20 0.72
▸ L3MBTL1 Q9Y468 2/20 0.72
▸ KDM4E B2RXH2 6/20 0.69
▸ LMNA P02545 5/20 0.69
▸ HPGD P15428 3/20 0.69
▸ RAB9A P51151 2/20 0.69
▸ ALOX12 P18054 2/20 0.69
▸ CYP1A2 P05177 1/20 0.69
▸ CYP3A4 P08684 1/20 0.69
▸ CYP2D6 P10635 1/20 0.69
▸ CYP2C19 P33261 1/20 0.69
▸ RECQL P46063 1/20 0.68
▸ PKM P14618 4/20 0.66
▸ POLB P06746 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL18040719 0.99 MAPT (0.73) MAPTGAAALDH1A1KMT2AHTT
SCHEMBL1684795 0.92 MAPT (0.77) MAPTGAAALDH1A1KMT2AHTT
Bromide SCHEMBL18040810 0.92 MAPT (0.79) MAPTGAAALDH1A1KMT2AHTT
SCHEMBL2353232 0.89 MAPT (0.72) MAPTGAAALDH1A1KMT2AHTT
SCHEMBL1684610 0.88 MAPT (0.56) MAPTGAAALDH1A1KMT2AHTT
Bromide SCHEMBL18040711 0.88 MAPT (0.73) MAPTGAAALDH1A1KMT2AHTT
Bromide SCHEMBL18040764 0.88 MAPT (0.57) MAPTGAAALDH1A1KMT2AHTT
SCHEMBL2356046 0.85 MAPT (0.68) MAPTGAAALDH1A1KMT2AHTT
SCHEMBL1684568 0.84 MAPT (0.98) MAPTGAAALDH1A1KMT2AHTT
SCHEMBL1684657 0.84 MAPT (0.84) MAPTGAAALDH1A1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 — — EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 — — US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 — — US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 — — EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 — — WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 — — EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 — — EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A MAPT 4026/4885GAA 3522/4885ALDH1A1 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback